Sagimet Biosciences inc (SGMT) Annual Balance Sheets

Annual · GAAP · USD millions
Access SGMT quarterly Balance Sheets →
Looking at balance sheet data from Sagimet Biosciences inc through provides insight into Dec 31 2025's solvency and capital structure over time.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
(Dec 31 2024) (Dec 31 2023)
Assets
Cash & cash equivalent35.02
Marketable Securities, Current SH78.10
Cash & Short-term Investments113.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current3.28
Total Current Assets116.40
Long-term investments0.00
Other Assets, Noncurrent0.08
Operating Lease Right Of Use Asset0.08
Total Assets116.48
Liabilities
Accounts Payable, Current AC1.31
Accrued Liabilities, Current AC3.71
Total Current Liabilities5.10
Total Long-term Debt0.00
Operating Lease Liability Current0.08
Total Liabilities5.10
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock457.61
Retained Earnings / Accumulated Deficit-346.35
Other Equity0.12
Common Stockholder's Equity111.38
Total Stockholder's Equity111.38
Liabilities & Stockholder's Equity116.48
4 historic quarters locked

Sign in to unlock the full Sagimet Biosciences inc balance sheet history.

About Sagimet Biosciences Inc Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001104659-26-026140

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License